Rediscovery of penicillin of psychiatry: haloperidol decanoate

References

• Van Os J, Kapur S. Schizophrenia. Lancet. 2009;374:635–645.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients With schizophrenia. JAMA Psychiatry. 2017;74(7):686–693.
   PubMed Web of Science ®Google Scholar
• Greene M, Yan T, Chang E, et al. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2017;29:1–8.
   Google Scholar
• San L, Bernardo M, Gomez A, et al. Socio-demographic, clinical and treatment characteristics of relapsing schizophrenic patients. Nord J Psychiatry. 2013;67:22–29.
   PubMed Web of Science ®Google Scholar
• Masand PS, Roca M, Turner MS, et al. Partial adherence to antipsychotic medicationimpacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry. 2009;11(4):147.
   PubMedGoogle Scholar
• Ravindranath BV. Metabolic syndrome in patients with severe mental illness undergoing psychiatric rehabilitation receiving high dose antipsychotic medication. Indian J Psychol Med. 2012;34:247–254.
   Google Scholar
• Peluso MJ, Lewis SW, Barnes TR, et al. Extrapyramidal motor side-effects of first-and second-generation antipsychotic drugs. Br J Psychiatry. 2012;200(5):387–392.
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Leslie DL, Sint KJ, et al. Cost-Effectiveness of long-acting injectable paliperidone palmitate versus haloperidol decanoate in maintenance treatment of schizophrenia. Psychiatr Serv. 2016;67(10):1124–1130.
   Web of Science ®Google Scholar
• First MB, Spitzer RL, Gibbon M, et al. Structured clinical interview for DSM-IV axis I disorders (SCID-I). Washington (DC): American Psychiatric Press; 1997.
   Google Scholar
• Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10(3):799–812.
   Web of Science ®Google Scholar
• Andreasen NC. Scale for the assessment of positive symptoms (SAPS). Iowa City: University of Iowa; 1984.
   Google Scholar
• Andreasen NC. The scale for the assessment of negative symptoms (SANS). Iowa City: University of Iowa; 1983.
   Google Scholar
• Hall RC. Global assessment of functioning. A modified scale. Psychosomatics. 1995;36(3):26775.
   Web of Science ®Google Scholar
• Simpson GM, Angus JW. Arating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11–19.
   PubMedGoogle Scholar
• Samara MT, Dold M, Gianatsi M, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016;73(3):199–210.
   PubMed Web of Science ®Google Scholar
• Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–777.
   PubMed Web of Science ®Google Scholar
• Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry. 2017;62(11):772–777.
   PubMed Web of Science ®Google Scholar
• Froemming JS, Lam YWF, Jann MW, et al. Pharmacokinetics of haloperidol. Clin Pharmacokinet. 1989;17(6):396–423.
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Toney G, Saklad SR, et al. A loading-dose strategy for converting from oral to depot haloperidol. Hosp Community Psychiatry. 1993;44(12):1155–1161.
   PubMedGoogle Scholar
• Deberdt R, Elens P, Berghmans W, et al. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. efficacy, dosage schedule and plasma levels. An open multicenter study. Acta Psychiatr Scand. 1980;62(4):356–363.
   Web of Science ®Google Scholar
• Vasavan Nair NP, Suranyi-Cadotte B, Schwartz G, et al. A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence. J Clin Psychopharmacol. 1986;6(1):30.
   Web of Science ®Google Scholar
• De Cuyper H, Bollen J, van Praag HM, et al. Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration. Br J Psychiatry J Ment Sci. 1986;148:560–566.
   Web of Science ®Google Scholar
• Nayak RK, Doose DR, Nair NP. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J Clin Pharmacol. 1987;27(2):144–150.
   Web of Science ®Google Scholar
• Divac NP, Prostran M, Jakovcevski I, et al. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:1–6.
   Web of Science ®Google Scholar
• Sumiyoshi T. Possible dose-side effect relationship of antipsychotic drugs: relevance tocognitive function in schizophrenia. Expert Rev Clin Pharmacol. 2008;1(6):791–802.
   PubMedGoogle Scholar
• Waraich PS, Adams CE, Roque M, et al. Haloperidol dose for the acute phase of schizophrenia (cochrane review). Cochrane Libr. 2004;2.
   Google Scholar
• Kamishima K, Ishigooka J, Komada Y, et al. Long term treatment with risperidone long-actinginjectable in patients with schizophrenia. Jpn. J. Psychiatry Neurol. 2009;12:1223–1244.
   Google Scholar
• Mason MN, Johnson CE, Piasecki M, et al. Ziprasidoneinduced acute dystonia. Am J Psychiatry. 2005;162(3):625–626.
   Web of Science ®Google Scholar
• Henderson JB, Labbate L, Worley M, et al. A case of acute dystonia after single dose of aripiprazole in a man with cocaine dependence. Amer J Addiction. 2007;16(3):244.
   Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectivenessof antipsychotic drugs in patients with chronic schizophrenia. New Eng J Med. 2005;353:1209–1223.
   PubMed Web of Science ®Google Scholar
• Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry. 2006;14(3):152–164.
   PubMed Web of Science ®Google Scholar
• Lammers L, Zehm B, Williams R, et al. Risperidone long-acting injection in schizophrenia spectrum illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada. BMC Psychiatry. 2013;13:155.
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Byerly M, Hamer R, et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA. 2014;311(19):1978–1987.
   PubMed Web of Science ®Google Scholar
• Zhao YJ, Lin L, Teng M, et al. Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials. BJPsych Open. 2016;2(1):59–66.
   Web of Science ®Google Scholar
• Crossley NA, Constante M, McGuire P, et al. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry. 2010;196:434–439.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Soczynska JK, Bordbar KB, et al. Antipsychotic-associated weight gain. In: Berbudes RA, Keck PE, McElroy SL, editors. Managing metabolic abnormalities in the Psychiatrically Ill. Washington, DC: American Psychiatry Association Publishing; 2007. p. 165–201.
   Google Scholar
• Francesco F, Cervone A. Metabolic alterations associated with first and second generation antipsychotics: a twenty-years open study. PsychiatrDanub. 2014;26(1):184–187.
   Google Scholar
• Meyer JM, Davis VG, McEvoy JP, et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1. Schizophr Res. 2008;103:104–109.
   PubMed Web of Science ®Google Scholar
• Falissard B, Mauri M, Shaw K, et al. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol. 2011;26:291–302.
   PubMed Web of Science ®Google Scholar
• De Hert M, Schreurs V, Sweers K, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res. 2008;101:295–303.
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160:290–296.
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments metaanalysis. Lancet. 2013;382:951–962.
   PubMed Web of Science ®Google Scholar
• Bulut SD, Bulut S, Tüzer V, et al. The effects of prolactin-raising and prolactin-sparing antipsychotics on prolactin levels and bone mineral density in schizophrenic patients. Nöro Psikiyatri Arşivi. 2014;51(3):205.
   Google Scholar
• David SR, Taylor CC, Kinon BJ, et al. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. ClinTher. 2000;22:1085–1096.
   Google Scholar
• Pérez-Iglesias R, Mata I, Martínez-García O, et al. Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis. J Clin Psychopharmacol. 2012;32(6):804–808.
   Web of Science ®Google Scholar
• Novick D, Haro JM, Bertsch J, et al. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the european schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2010;30(5):531–540.
   PubMed Web of Science ®Google Scholar
• Marcus SC, Zummo J, Pettit AR, et al. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm. 2015;21(9):754–768.
   PubMed Web of Science ®Google Scholar
• Warikoo N, Chakrabarti S, Grover S, et al. Adherence and continuation of treatment with first-and second-generation antipsychotics in schizophrenia. Indian J Psychol Med. 2014;36(1):33.
   Google Scholar
• Nielsen J, Jensen SO, Friis RB, et al. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study. Schizophr Bull. 2015;41(3):627–636.
   PubMed Web of Science ®Google Scholar
• Hudson T, Owen R, Thrush C, et al. A pilot study of barriers to medication adherence in schizophrenia. J Clin Psychiatry. 2004;65:211–216.
   PubMed Web of Science ®Google Scholar
• Loffler W, Kilian R, Toumi M, et al. Schizophrenic patients’ subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry. 2003;36:105–112.
   PubMed Web of Science ®Google Scholar
• Taylor DM, Young CL, Mace S, et al. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry. 2004;65:1076–1083.
   PubMed Web of Science ®Google Scholar